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Abstract
Background: Microsatellite instability (MSI) resulting from inactivation of the DNA mismatch repair system (MMR)
characterizes a highly immunological subtype of colorectal carcinomas. Those tumors express multiple frameshift-mutated
proteins which present a unique pool of tumor-specific antigens. The DNA MMR protein MSH3 is frequently mutated in MSI
+
colorectal tumors, thus making it an attractive candidate for T cell-based immunotherapies.
Methodology/Principal Findings: FSP-specific CD8
+ T cells were generated from a healthy donor using reverse immu-
nology. Those T cells specifically recognized T2 cells sensitized with the respective peptides. Specific recognition and killing
of MSI
+ colorectal carcinoma cells harbouring the mutated reading frame was observed. The results obtained with T cell
bulk cultures could be reproduced with T cell clones obtained from the same cultures. Blocking experiments (using
antibodies and cold target inhibition) confirmed peptide as well as HLA-A0201-specificity.
Conclusions: We identified two novel HLA-A0201-restricted cytotoxic T cell epitopes derived from a (-1) frameshift mutation
of a coding A(8) tract within the MSH3 gene. These were
386-FLLALWECSL (FSP18) and
387-LLALWECSL (FSP19) as well as
403-
IVSRTLLLV (FSP23) and
402-LIVSRTLLLV (FSP31), respectively. These results suggest that MSH3(-1) represents another
promising MSI
+-induced target antigen. By identifying two distinct epitopes within MSH3(-1), the sustained immunogenicity
of the frameshift mutated sequence was confirmed. Our data therefore encourage further exploitation of MSH3 as a piece
for peptide-based vaccines either for therapeutic or –even more important– preventive purposes.
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Introduction
Loss of the DNAmismatchrepair(MMR)systemby(epi-) genetic
alterations leads to an increased mutation rate in short, tandemly
repeated sequences, termed microsatellites. This phenomenon,
commonly referred to as microsatellite instability (MSI),is presented
by length variations in tracts of mono- or polynucleotides.
Clinically, MSI is found in .90% of patients affected by the
hereditary non-polyposis colorectal carcinoma (HNPCC) syn-
drome, as well as in several sporadic malignancies including
tumors of the colorectum, the stomach and the endometrium,
where it is found in up to 15% of cases. When comparing with
microsatellite stable tumors, there is some evidence for –at least
partial– immunological growth control in MSI cancers, like (I) the
dense local lymphocytic infiltration (‘‘Crohn’s-like lymphocytic
reaction’’), (II) the increased apoptotic tumor cell number, and (III)
the low number of distant metastases that (IV) leads to an
improved overall patient survival [1–3]. Beyond that, there is
evidence that MMR deficient cells are intrinsically resistant to
methylating agents and to some antimetabolites, including the
chemotherapeutic drug 5-Fluorouracil, which is standard in adju-
vant treatment of colorectal carcinoma (CRC) [4].
In the multistep process of carcinogenesis, mutations affecting
genes, whose alterations are advantageous to the tumor cell, will
be positively selected. In MSI
+ cancers, several genes being
especially prone to MSI have been identified with the transforming
growth factor beta receptor II (TGFbRII) being one of the first.
Other examples of so-called MSI target genes frequently mutated
in CRC include Caspase-5, ACVR2, and AIM2 [5,6].
From a biochemical point of view, MSI affecting coding regions
of genes leads to frameshift mutations and the synthesis of C-
terminally modified proteins. The resulting altered proteins
typically lack normal functionality but additionally, they constitute
neo-epitopes, when presented in the context of MHC molecules at
the tumor cells’ surface. In recent years, our group was leading in
demonstrating the high immunogenicity of MSI-induced frame-
shift-peptides (FSP) by identifying numerous epitopes recognized
by T cells [7–10]. Using the classical reverse-immunology
approach, T cells from healthy HLA-A0201
+ donors are stimu-
lated by synthetic FSPs. Importantly, the outgrowing T cells are
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+ cytotoxic T lymphocytes (CTL) capable to effec-
tively lyse cells harbouring the respective mutation [7,10,11,12].
Based on these in vitro studies, Schwitalle et al. provided evidence
for FSP-specific immune responses not only in HNPCC patients
but also in still healthy HNPCC germline mutation carriers [13].
This study additionally revealed that FSPs are recognized by
the human immune system and thus represent relevant tumor
antigens in vivo.
Hence, FSPs are very interesting targets for specific immuno-
logical approaches both for therapeutic and –even if currently
hypothetical–for preventive purposes. Since an effective tumor
vaccine ideally contains epitopes derived from several tumor-
specific antigens, the identification of additional, relevant T cell
epitopes is imperative.
Here, we describe the identification of HLA-A0201-restricted
CTL epitopes generated by a MSI
+ tumor specific frameshift
mutation in a cMS of the MSH3 gene. MSH3 is one of the DNA
MMR genes located on chromosome 5q14.1. It belongs to the
MutS family and mutations are found in about 40% of colorectal
and stomach cancers, as well as in .50% of established CRC cell
cultures [14]. Functional loss of this protein was found to play a
role in the progression of MMR-deficient tumors by increasing
instability [15]. Therefore, mutated MSH3 shows several charac-
teristics an ideal tumor antigen should have and thus constitutes
another important candidate for the development of immune-
based MSI
+ tumor targeting strategies.
Materials and Methods
Peptides
HLA-A0201-restricted peptides against the (-1) mutation of a
A(8) tract within the MSH3 gene were selected on the basis of two
peptide-motif scoring systems as described before [9]. Using these
methods, 12 peptides were selected as candidate T cell epitopes
including six 9-mer, and six 10-mer peptides. Peptides were
purchased from the Peptide Synthesis Facility of the German
Cancer Research Center, dissolved in DMSO (5 mg/ml) and
further diluted in PBS (500 mg/ml). A complete list of peptides
used in this study is provided in Table 1.
Cell lines
All tumor cell lines were obtained from the German Collection
of Microorganisms and Cell Cultures (Braunschweig, Germany) or
from Cell Lines Services (Eppelheim, Germany) tumor bank and
grown in RPMI 1640 medium supplemented with 10% fetal calf
serum (FCS) and 2 mmol/L L-glutamine. The MSI
+ colorectal
carcinoma cell lines HCT116 [HLA-A0201
+; MSH3(-1)], and
Colo60H [HLA-A0201
+; MSH3(-1)], as well as HLA-A0201
+ T2
cells, exogenously loaded with peptide, were used for functional
analysis. As controls, the MSS colorectal carcinoma cell lines
SW480 and SW707 [both HLA-A0201
+] as well as the ery-
throleukemic HLA
2 cell line K562 were applied. All tissue culture
media and supplements were purchased from PAA (Co ¨lbe,
Germany) unless indicated otherwise. IL-4, IL-7, and IFN-c were
obtained from Cellgenix (Freiburg, Germany); Proleukine (IL-2)
was obtained from Novartis (Nu ¨rnberg, Germany). The cells were
maintained in a humidified 37uC incubator with 5% CO2.
Generation of CD40-activated B cells & Peptide-specific T
cell stimulation
All procedures were performed as described before [10]. Briefly,
peripheral blood mononuclear cells (PBMC) were isolated from a
buffy coat of a healthy HLA-A0201
+ donor by ficoll-density
gradient centrifugation. The use of buffy coats for scientific
investigations has been approved by the institutional review board
of the university of Heidelberg.
Thereafter, T cells were purified by magnetic depletion of non
T cells using the Pan T cell isolation kit II (Miltenyi Biotec,
Bergisch-Gladbach, Germany) according to the manufacturer’s
instructions.
CD40-activated B cells (CD40Bs) were generated from the same
healthy HLA-A0201
+ donor via NIH/3T3 feeder cells, stably
transfected with human CD154. Outgrowing CD40Bs were
restimulated every 3–4 days. CD40 Bs were irradiated (30 Gy),
incubated with peptide (10 mg/ml; peptides were applied as mixes
of four peptides each) in serum-free IMDM for 1 hour at 37uC,
and washed to remove excess of peptide. Then the CD40 Bs were
Table 1. Frameshift and control peptides used in this study.
Protein Accession number
a Name Peptide
b Theoretical Scores
c
Fluorescence Index
d
Ken Parker SYFPEITHI
MSH3(-1) AAB47281 FSP17
389-ALWECSLPQA 389 24 4.42
MSH3(-1) AAB47281 FSP18
386-FLLALWECSL 364 25 4.85
MSH3(-1) AAB47281 FSP19
387-LLALWECSL 36 26 1.16
MSH3(-1) AAB47281 FSP20
394-SLPQARLCL 21 23 0.05
MSH3(-1) AAB47281 FSP21
402-LIVSRTLLL 5 23 0.01
MSH3(-1) AAB47281 FSP22
401-CLIVSRTLL 21 22 0.2
MSH3(-1) AAB47281 FSP23
403-IVSRTLLLV 24 21 0.13
MSH3(-1) AAB47281 FSP24
382-KRATFLLAL 0.1 20 0.01
MSH3(-1) AAB47281 FSP31
402-LIVSRTLLLV 37 25 0.2
MSH3(-1) AAB47281 FSP32
394-SLPQARLCLI 24 24 0.01
MSH3(-1) AAB47281 FSP33
401-CLIVSRTLLL 21 23 1.98
MSH3(-1) AAB47281 FSP34
399-RLCLIVSRTL 4 22 0.34
aProtein or nucleotide accession numbers are indicated;
bPosition of the start amino acid in the protein is indicated;
cPredicted binding scores to HLA-A0201 using computer-assisted analysis;
d(mean fluorescence with peptide - mean fluorescence without peptide)/(mean fluorescence without peptide).
doi:10.1371/journal.pone.0026517.t001
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4:1 in T cell medium (IMDM containing 10% FCS, 2 mmol/l L-
glutamine, and antibiotics), supplements (1:100), and IL-7 (10 IU/
ml). T cells were restimulated every 7 days; IL-7 was replaced by
IL-2 (100 IU/ml) from day 28 on. T cell cultures were repeatedly
characterized by flow cytometry following extracellular and intra-
cellular staining protocols as described [9].
Cloning of FSP-specific T cells by limiting dilution from T
cell bulk cultures
Cloning of FSP18, 19, 23, and 31-specific cytotoxic T lym-
phocytes (CTL) was performed by limiting dilution of the T cell
bulk culture. Hence, T cells (0.7 cells/well) were added to V-
bottomed 96-well plates containing 3610
5 lethally irradiated
(30 Gy) peptide-loaded autologous CD40Bs at a final volume of
200 ml IMDM (supplemented with 10% FCS, supplements
(1:100), and IL-2 (100 IU/ml)). This treatment was repeated
weekly for restimulation of T cells. After 4–6 weeks, specificity of
outgrowing T cells was tested in IFN-c-ELISpot (Enzyme-linked
immunospot) assays.
ELISpot assays
ELISpot assays were accomplished using nitrocellulose-lined 96-
well-plates (Multiscreen, Millipore, Bedford, MA, USA) covered
with mouse anti-human IFN-c mAb (Mabtech, Nacha, Sweden)
and blocked with serum-containing medium. T cells (1610
4 cells/
well) were then added to each well along with T2 target cells
(3.5610
4 cells/well), which had been preincubated with cognate
peptides (1.5 mg/well) or with irrelevant control peptide (
128-
YLLPAIVHI from P68) as a negative control. Following 16 hours
incubation in a 5% CO2 humidified chamber at 37uC, the wells
were washed vigorously six times with PBS-Tween (PBS+0.05%
Tween-20) and incubated with a biotinylated rabbit anti-human
IFN-c mAb for 4 h, washed again, incubated with streptavidin–
alkaline phosphatase for 2 h, and washed again. Spots were
visualized by incubation with BCIP/NBT (Sigma-Aldrich, Stein-
heim, Germany) for up to 1 h. The reaction was stopped with tap
water, and after drying, the spots were counted using the KS-
ELISpot reader (Zeiss Kontron, Go ¨ttingen, Germany).
To confirm HLA-A2
+ restriction of FSP-specific CTLs,
antibody-blocking ELISpots were performed. FSP-loaded T2
were incubated with the monoclonal antibodies anti-HLA-A2
(clone BB7.2) and pan-anti-MHCI (clone W6/32) and T cells with
anti-CD3 (clone OKT3) and anti-CD8 (clone OKT8).
Chromium release assay
Standard chromium release assays were performed as described
[9]. The percentage of specific lysis was calculated as follows:
%specific lysis~ 100|experimental release{spontaneous release ðÞ
= jjmaximum release{spontaneous release ðÞ
Results
Induction of highly activated cytotoxic T cells specific for
MSH3(-1)-derived peptides
FSP-specific T cell bulk cultures were generated from a healthy
HLA-A0201
+ donor using mixes of hypothetically immunogenic
peptides, generated by a (-1) frame of the MSH3 gene. In order not
to miss a potential T cell epitope, different peptides, including six 9-
mersand six 10-mers,weretested (see Table 1 for details). Forinitial
T cell stimulation experiments, peptide pools, consisting each of
four peptide sequences, were applied. Autologous CD40Bs were
employed as antigen presenting cells. These CD40Bs were loaded
with peptide mixes and used for weekly restimulation of T cells.
With this method, three different FSP-specific T cell bulk
cultures were successfully established. Following seven to eight
weeks of restimulation, T cell numbers increased .100-fold in
each culture (data not shown). Detailed flow cytometric charac-
terization of proliferating T cell cultures revealed generation of
highly pure and activated T cells. As can be depicted from Table 2,
cell surface as well as intracellular staining of T cells stimulated
against FSPs 31–34 identified that the bulk culture consisted
primarily of CD8
+ cytotoxic T cells at day 35. Further culture
resulted in a nearly exclusive cytotoxic phenotype (CD8
+: 97.1%
at day 98 of culture). Most of these T cells expressed high levels of
the activation markers CD25 (98.1%) and CD71 (99.4%).
Intracellular staining showed that a significant part of these
cytotoxic T cells were positive for TNF-a, IFN-c, and granzyme B,
while the minority expressed IL2 and perforin (Table 2). Similar
results were obtained for the two other T cell bulk cultures
generated against FSP 17–20 and FSP 21–24 (Table 2).
Recognition and killing of peptide-loaded T2 cells by T
cell bulk cultures
Next, peptide recognition and target cell killing of the expanded
T cell bulk cultures was determined. FSP-specificity was examined
using T2 cells exogenously loaded with the respective peptides. T2
cells loaded with irrelevant peptide (P68) served as negative
control.
As can be depicted from Figure 1A, T cells that had been raised
against a mixture of FSP17–20 exhibited a very strong response
towards
386-FLLALWECSL (FSP18) and
387-LLALWECSL
(FSP19). The number of IFN-c secreting T cells was comparable
Table 2. FACS analysis of the T cell bulk culture.
Antigen Tc bulk culture (% positive cells)
Tc FSP17–20 Tc FSP21–25 Tc FSP31–34
CD2
1 91.7 98.6 99.4
CD3
1 99.5 99.7 99.5
CD4
1/3 22.4/1.7 35.8/6.7 28.1/5.0
CD8
1/3 71.0/97.1 68.9/91.5 67.8/94.9
CD28
1 64.8 84.4 79.5
CD45R0
1 66.3 94.7 94.5
CD49d
1 80.7 88.0 79.5
CD50
1 99 99.7 99.6
CD25
1/3 16.8/94.1 38.3/96.9 36.2/98.1
CD69
1/3 35.5/43.9 13.9/73.5 36.4/45.7
CD71
3 99.5 99.2 91.6
IFN-c
2 68.6 73.6 42.9
TNF-a
2 ND ND 66.9
IL-2
2 ND ND 22.5
Perforin
2 11.6 13.2 11.1
Granzyme B
2 96.1 92.5 97.5
1d35 of Tc culture, extracellular staining;
2d86 of Tc culture, intracellular staining;
3d98 of Tc culture, extracellular staining; ND - not done.
doi:10.1371/journal.pone.0026517.t002
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recognition of these peptide sequences. Both peptides cover the
same epitope with FSP18 being a 10mer peptide and FSP19 a
9mer peptide. Thereafter, specific killing activity of these T cells
was investigated. They effectively lysed T2 cells loaded with both
FSP18 and 19 (Figure 1B). Interestingly, minor T cell reactivity
was observed towards FSP17 in ELISpot assays and accordingly
lysis of FSP17-loaded T2 cells was less efficient (Figure 1B).
Contrary, FSP17–20 bulk T cells displayed no recognition of
FSP20 and this peptide was not analyzed further.
Testing of the CTLs stimulated against FSP21–24 revealed an
exclusive recognition of the peptide
403-IVSRTLLLV (FSP23),
while reactivity was completely absent towards the other peptides
present in this mix (Figure 1C). In a subsequent cytotoxicity assay,
T cells exhibited pronounced lytic potential towards FSP23-loaded
T2 cells (Figure 1D).
Analysis of the FSP31–34 T cell bulk culture revealed a strong
recognition of
402-LIVSRTLLLV (FSP31) and
394-SLPQARLCLI
(FSP32) in IFN-c-ELISpot assays. Approximately 1.5 and 1.9%
(FSP31 and 32, respectively) of the T cells specifically secreted
IFN-c in response to peptide loaded T2 targets (Figure 1E). How-
ever, cytolytic activity was observed exclusively towards FSP31-
loaded T2 cells. FSP32 did not elicit a reaction (Figure 1F).
Moreover, there was no detectable recognition of FSP33 and 34.
Taken together, these data provide clear evidence for the ge-
neration of T cell cultures specific for several epitopes generated
by the MSI-induced (-1) frameshift mutation of MSH3.
Reactivity towards MSI
+ colorectal tumor cells
To analyze, if the observed reactivity against MSH3(-1)-derived
peptides was confined to peptide-loaded target cells, killing activity
towards MSI
+ tumor cells was examined. FSP17–20 CTL bulk
cultures specifically recognized the MSI
+ CRC cell lines HCT116
and Colo60H, which express a (-1) version of MSH3 endogenously
(Figure 2A, left panel). Susceptibility of HCT116 towards T cell
mediated killing was slightly enhanced by IFN-c pre-treatment
(Figure 2A, right panel) which leads to an upregulation of MHC-I
and HLA-A0201 on this tumor cell line [9]. Comparable results
were obtained for T cells raised against FSP21–24 and FSP31–34.
As can be depicted from Figure 2B and C, T cells effectively
eliminated target cells harbouring the underlying MSH3(-1)
mutation. Again, killing potential was increased by overnight
treatment of HCT116 cells with IFN-c (Figure 2B and C, right
panel).
This reactivity was likely to be specific since none of the CTL
bulk cultures reacted towards the HLA-A0201
+ but microsatellite
stable cell lines SW480 and SW707. Moreover, unspecific NK
cell-mediated killing could be excluded by lacking reactivity
towards the classical NK cell target K-562 (Figure 2).
In summary, these results provide evidence for the recognition
of several MSH3(-1) peptides presented in HLA-A0201 molecules
after endogenous expression and proteasomal processing.
Generation of FSP-specific T cell clones by limiting
dilution from CTL bulk cultures
The gold standard in T cell epitope discovery is the con-
firmation of target cell recognition using T cell clones. Hence, we
next established clones by classical limiting dilution of all three
CTL bulk cultures showing strong reactivity in ELISpot and cyto-
toxicity assays. Precisely, this was done using autologous CD40Bs
loaded with FSP18, 19, 23, and 31.
Following several weeks of restimulation, outgrowing T cell
clones were harvested. Twenty-four CTL clones specific for FSP18
were obtained. In subsequent cytotoxicity assays, six of these
clones were capable to lyse peptide-loaded T2 targets (Table 3).
Next, the lytic activity of FSP18-specific T cell clones towards
Figure 1. IFN-c ELISpot and
51Cr-release assays. FSP-specific T cells were stimulated against MSH3(-1) derived peptide mixes FSP17–20, FSP21–
24, and FSP31–34. Thereafter, outgrowing T cell cultures were incubated for 5 h with peptide-loaded T2 cells as described in ‘‘material and methods’’.
(A, C and E) show the number of IFN-c releasing T cells (B, D and F) show cytotoxic activity of FSP-specific T cells. Results are displayed as the mean
and standard deviation from analysis performed in triplicate.
doi:10.1371/journal.pone.0026517.g001
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+ tumor cells was investigated. Two clones effectively killed
HCT116cellswith one clonedisplayingadditionalreactivityagainst
Colo60H. Comparable results were obtained for FSP19. Of the 46
obtained CTL clones, FSP19-loaded T2 cell lysis was induced by 12
clones. Of those, eight were reactive towards HCT116 cells, and
two clones also lysed Colo60H targets (Table 3).
A total of 66 FSP31-specific clones were established. Of note, 44
clones effectively lysed FSP31-loaded T2 cells, 18 of those clones
specifically killed HCT116 targets but only two clones were highly
reactive towards Colo60H cells.
Finally, from the 20 generated FSP23 clones, only three exhi-
bited killing activity towards FSP23-loaded T2 cells. Two of these
clones were capable of lysing HCT116 tumor cell targets but no
reactivity was observed against Colo60H cells (Table 3).
To sum up these data, we could identify two distinct epitopes
showing sustained immunogenicity out of the (-1) MSH3 fra-
meshift mutated sequence. These are
386-FLLALWECSL (FSP18)
and
387-LLALWECSL (FSP19), respectively as well as
403-
IVSRTLLLV (FSP23) and
402-LIVSRTLLLV (FSP31), respec-
tively.
Specific HLA-A0201-restricted recognition of MSH3(-1)
tumor cells by FSP31-specific T cell clones
Selected FSP31-specific CTL clones demonstrating reactivity
towards tumor cell targets were further analyzed in close detail.
Figure 2. Functional recognition of target cells by FSP specific T cells. Specific lysis of HLA-A0201
+ cell lines harbouring a (21) version of
MSH3 (left panel). Specificity was confirmed by lack of reactivity against the colorectal carcinoma cell lines SW480 and SW707 (HLA-A0201
+, MSH3
(wt)). Lytic potential was slightly enhanced by pre-treatment of HCT116 cells with IFN-c for 24 h (left panel). T,arget cell lysis is depicted at different
effector to target cell (E:T) ratios. All results are displayed as the mean and standard deviation from analysis performed in triplicate.
doi:10.1371/journal.pone.0026517.g002
Table 3. FSP-specific CTL clones and lysis of target cells.
Lysis of
Name Peptide Clones T2 HCT116 Colo60H
FSP18
386-FLLALWECSL 24 6 2 1
FSP19
387-LLALWECSL 46 12 8 2
FSP23
403-IVSRTLLLV 20 3 2 -
FSP31
402-LIVSRTLLLV 66 44 18 2
doi:10.1371/journal.pone.0026517.t003
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cell clones.
In antibody blocking experiments, HLA-A0201 restricted target
cell recognition by FSP31-specific T cell clones was confirmed. As
can be taken from Figure 3, IFN-c release by CTLs in response to
FSP31-loaded T2 cells was substantially inhibited by antibodies
interfering with MHC-I on the target cell side (HLA-A2 and pan-
MHC-I) as well as CD3, CD8 and CD28 on the T cell side.
Additionally, FSP31 specificity and HLA-A0201 restriction of
CTL clones could be confirmed in cold-target inhibition ex-
periments by adding an excess of unlabeled T2 target cells into
standard
51Cr-release assays (Figure 4). In these analysis, lysis of
labeled FSP31-loaded T2 cells was substantially inhibited when an
excess of unlabeled T2 cells loaded with FSP31 was present, but
not when these unlabeled T2 cells were loaded with an irrelevant
peptide (P68). Effects were most obvious for clones A6 and 5H10
followed by A3 (Figure 4A). In additional blocking experiments
HCT116 cells were used as target cells. Tumor cell lysis of the
clones was effectively inhibited by adding an excess of FSP31
loaded T2 cells. T2 cell pulsed with the irrelevant peptide P68 had
only minor effect on the tumor cell killing activity (Figure 4B).
Thus, this provides strong evidence for HLA-A0201 restriction
and recognition of endogenous FSP31 of these CTL clones.
Finally, we performed antibody blocking kill assays. Here, the
reactivity against HCT116 could be blocked approximately half by
antibodies against the T cell receptor CD3 and against both pan-
MHC-I and HLA-A2 (Figure 4C).
Discussion
Vaccination strategies aiming to specifically act on tumor target
antigens have now come to the fore. Ideally, an efficient antitumor
immunotherapy involves a multi-epitope strategy including T-cell
epitopes from a set of highly immunogenic tumor-associated
antigens and several different HLA-class I restriction elements.
However, most of the tumor antigens identified so far may not
constitute perfect target structures since antigen down-regulation
or loss can occur during immunotherapy. Hence, there is a need
for further identification of relevant T cell epitopes.
MSI leads to production of abnormal proteins predominantly
constituting of frameshift mutants that represent neo-antigens to
the immune system and thus may elicit spontaneous immune
responses. Indeed, MSI
+ tumors often exhibit marked lymphocytic
infiltration, especially at the tumor invasion front in the stromal
compartment, with a predominance of activated CD8
+ T cells
[16]. Consequently, it has been suggested that this may even be
causative for the better prognosis observed for MSI
+ CRC when
compared to their MSS counterpart [3]. Whether the observed T
cell responses are directly associated with the higher apoptosis rate
of MSI
+ tumor cells or whether this is just a coincidence is largely
unsolved [16]. On the contrary, there is a correlation between the
overall number of frameshift mutations and tumor-infiltrating
lymphocyte density, arguing for the clinical relevance of T cell-
based immunotherapies.
In the last decade, a number of MSI-induced CD4
+ and CD8
+
T cell epitopes derived from FSPs have been identified by us and
others [7–12]. The relevance of these FSPs as tumor-specific
antigens in vivo was only recently shown by providing evidence for
the presence of FSP-specific immune responses not only in MSI
+
CRC patients, but also in still healthy HNPCC germline mutation
carriers [13]. This observation is a striking argument in favour of a
substantial contribution to tumor growth control by FSP-specific T
cells in vivo, making those peptides very interesting candidates for
the development of targeted vaccination strategies. There are,
however, still surprisingly few frameshift epitopes characterized
and consequently, in order to identify the best frameshift
candidates for future MSI-specific immunotherapeutic approach-
es, more must urgently be defined.
We here identified two epitopes derived from a (-1) frameshift
mutation of a coding A(8) tract within the DNA MMR gene
MSH3. These antigenic epitopes could be good candidates for
immunotherapy, because mutations in the MSH3 gene, along with
others, e.g. TGFbRII, BAX and MSH6, appear to play an active
role in tumor progression [17]. By examining the sequence and
timing of target gene alterations, it was reported that MSH3
mutations are rather late events in the multistep process of car-
cinogenesis, probably promoting metastasis or recurrence [18,19].
Of note, MSH3-deficient MSI-low CRCs, corresponding with
multiple tetranucleotide frameshifts, have poor clinical outcomes,
indicative for driving metastasis in MSI-low CRC, too [20].
By using the strategy of reverse immunology, T cells from a
HLA-A0201
+ donor were stimulated against a pool of different
peptides. Peptides were selected on algorithm-predicted candidate
epitopes, hypothetically binding with high affinity to HLA-A0201
molecules thus forming stable MHC/peptide complexes. All three
polyclonal bulk T cell cultures grew well and FSP-specific reac-
tions could be observed towards half of the twelve MSH3(-1)-
derived peptides included into this analysis. Of particular rele-
vance was the finding that T cell mediated tumor cell recognition
and lysis could be detected towards MSI
+ CRC cancer cells
Figure 3. Antibody blocking ELISpot. FSP-specific CTLs were stimulated against T2 cells either loaded with FSP31 or irrelevant peptide (P68).
HLA-specificity was examined by blocking MHC-I on the target cell side (HLA-A2 and pan-MHC-I). Inhibition of IFN-c release was confirmed by
blocking CD3, CD8 and CD28 on the T cell side. The number of IFN-c releasing T cells is given. Results are displayed as the mean and standard
deviation from analysis performed in triplicate.
doi:10.1371/journal.pone.0026517.g003
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in line with our previous studies and thus extends our knowledge
on MSI-derived tumor specific antigens being recognized by
cytotoxic T cells [7–10].
By generating FSP-specific CTL clones, we were able to identify
two distinct epitopes within MSH3(-1). Since those peptides show
no common motif, this formally proofs the induction of (clonally)
different T cell responses recognizing the same mutation. Our
results show that several MSH3(-1) epitopes can be recognized on
tumor cells following natural expression and proteasomal pro-
cessing. However, the detailed analysis of a high number of CTL
clones raised against several FSPs also hints towards a high heter-
ogeneity between clones. Many clones strongly reacted against
peptide-loaded target cells (65 of 156). But more than half of those
were not able to recognize tumor cells carrying the underlying
mutation (35 of 65 did not react). To explain this interesting
finding, one may speculate, that T cells of lower avidity fail to effi-
ciently lyse tumor target cells presenting endogenously generated
FSP, whereas T cells of high avidity can react against targets
displaying low peptide levels.
Furthermore, most of the remaining clones recognizing
HCT116 (30) failed to lyse Colo60H (only 5 reacted). Several
reasons may explain this finding. Colo60H is generally a poorer
target than HCT116 [9 and own unpublished data]; this may for
example be contributable to a higher intrinsic resistance towards
CTLs. Moreover, surface expression levels of HLA-A2 may differ;
but in FACS-analysis we found very similar HLA-A2 expression of
the two CRC cell lines (data not shown). Finally, differences in the
levels of either MSH3(-1) protein expression or of (peptide)-antigen
presentation between HCT116 and Colo60H might be a plausible
explanation for this observation. This is an interesting question
which shall be addressed in future studies.
In summary, the data presented here suggest that the MSH3(-1)
frameshift constitutes – from an immunological point of view – one
of the major molecular alterations that take place in MSI
+ tumors.
However, our data are to some extent in conflict to the findings
of a pioneer work performed by Williams and colleagues [21].
They very recently analyzed the sensitivity of MSI-induced
frameshift mutations towards nonsense mediated RNA decay
and found MSH3(-1) to be decay-sensitive [21]. This finding has
two major aspects. First, when MSH3(-1) mRNA is degraded very
fast, our observed sensitivity of endogenously MSH3(-1) expressing
tumor cells towards specific T cells implies that the described epi-
topes must be very immunogenic and the raised T cells must be of
high avidity. Contrary to that it would secondly raise concerns
about the potential of MSH3(-1) protein to be cross-presented by
professional antigen-presenting cells and thus would substantially
limit it’s usefulness as MSI-specific tumor antigen. We here want
to bring forward several arguments in favour of the highly
immunogenic character of MSH3(-1). A weaker argument would
be that all the T cell epitopes derived from cMS that have
been described so far [7–12] are predicted to be sensitive for
Figure 4. Cold target inhibition. FSP-specificity of four different CTL clones (A3, A6, 5A8 and 5H10) was examined. Firstly, an excess of unlabeled
T2 cells either pulsed with FSP31 or with irrelevant peptide (P68) were added into experimental wells. Experiments were performed using (A) T2 and
(B) HCT116 as target cells. Lysis of unpulsed HCT116 or exogenously FSP31-loaded T2 cells without cold targets served as control. Killing of target
cells is depicted at different effector to target cell (E:T) ratios. Secondly, recognition of HCT116 CRC target cells of two clones was blocked by addition
of antibodies against CD3, HLA-A2 and pan-MHC-I at an E:T ratio of 10:1. All results are displayed as the mean and standard deviation from analysis
performed in triplicate.
doi:10.1371/journal.pone.0026517.g004
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found to be naturally presented and specific T cells could
efficiently kill tumor cells endogenously expressing the underlying
mutation. Then again, both T cell as well as antibody responses
specific for cMSI-induced frameshift antigens have been observed
in patients as well as healthy HNPCC mutation carriers [13,22].
A major obstacle of immunotherapy as a whole is the obvious
fact, that a tumor mass – a large and heterogeneous ensemble of
genetically unstable cells – uses different mechanisms that will
possibly allow at least some tumor cells to survive the highly
specific immune attack that can be induced by a single T-cell
epitope. In this regard, strategies based on the combination of
multi-epitope immunotherapeutic approaches with standard
(chemo) therapies may finally be clinically most effective.
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